Cannabichromevarin

Cannabichromevarin (CBCV) is a minor cannabinoid that acts as a TRPA1 channel activator and CB2 receptor modulator. Preliminary research indicates potential anti-tumor and anti-inflammatory effects through cannabinoid receptor pathways.

Origin & History

Cannabichromevarin (CBCV) is a naturally occurring phytocannabinoid found in trace amounts (<0.1% by dry weight) in Cannabis sativa plants. It is a propyl cannabinoid with a three-carbon alkyl side chain (C₁₉H₂₆O₂, molecular weight 286.4 g/mol) and is typically extracted using solvent-based or supercritical CO₂ extraction methods.

Historical & Cultural Context

CBCV has no documented traditional medical use as it is a minor cannabinoid present only in trace amounts and was not specifically isolated or utilized in traditional medicine systems. Its study is entirely a product of modern phytochemical research post-2000s, unlike cannabis itself which has extensive traditional use.

Health Benefits

• Anti-tumor potential: In vitro studies show cytotoxic effects against breast and colon cancer cell lines (evidence: preliminary cell culture only)
• Anti-inflammatory properties: Preliminary in vitro research indicates potential anti-inflammatory effects (evidence: cell-based studies only)
• Antibacterial activity: Cell-based studies suggest effectiveness against certain bacterial strains including drug-resistant organisms (evidence: in vitro only)
• Antioxidant neuroprotection: In vitro evidence indicates potential neuroprotective effects through oxidative stress reduction (evidence: cell culture only)
• Pain management potential: Preliminary in vitro research suggests analgesic properties (evidence: cell-based studies only)

How It Works

Cannabichromevarin primarily activates TRPA1 (transient receptor potential ankyrin 1) channels and modulates CB2 cannabinoid receptors. The compound appears to influence inflammatory cascades by inhibiting pro-inflammatory cytokine production, particularly TNF-α and IL-6. CBCV may also interact with vanilloid receptors (TRPV1) to produce therapeutic effects.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses of CBCV have been published in peer-reviewed literature. All current evidence consists entirely of in vitro (cell culture) and preclinical animal studies, with no PubMed PMIDs available for human trials because none exist.

Clinical Summary

Current evidence for cannabichromevarin is limited to preliminary in vitro studies using isolated cell cultures. Cell-based research shows cytotoxic effects against MCF-7 breast cancer and HT-29 colon cancer cell lines, though specific IC50 values have not been established. Anti-inflammatory studies demonstrate reduced inflammatory marker expression in activated immune cells. No human clinical trials or animal studies have been published to date, making therapeutic claims premature.

Nutritional Profile

Cannabichromevarin (CBCV) is a non-psychoactive phytocannabinoid and homolog of cannabichromene (CBC), classified as a trace compound found in Cannabis sativa. It is not a nutritional ingredient and contains no meaningful macronutrients (carbohydrates, proteins, or fats), micronutrients, vitamins, or dietary fiber in any biologically relevant quantity. CBCV is a propyl-chain analog of CBC, differing by the substitution of a pentyl side chain with a propyl side chain, resulting in a molecular formula of C19H26O2 and a molecular weight of approximately 286.41 g/mol. As a terpenophenolic compound, its bioactive concentration in raw cannabis plant material is typically below 1% by dry weight, often in the range of trace to 0.1–0.5% in select cultivars. It belongs to the cannabinoid class of bioactive compounds, interacting primarily with transient receptor potential (TRP) channels (notably TRPA1 and TRPV1) rather than CB1 or CB2 receptors with high affinity. Bioavailability data specific to CBCV is not yet established in human studies; however, by structural analogy to other propyl-chain cannabinoids (e.g., THCV, CBDV), oral bioavailability is expected to be low due to first-pass metabolism and high lipophilicity (estimated logP ~5–6), with improved absorption in lipid-rich delivery matrices. No caloric value, mineral content, or vitamin contribution is documented.

Preparation & Dosage

No clinically established dosage ranges exist for CBCV in humans as no human clinical trials have been conducted. There are no evidence-based dosing recommendations for any formulation (extract, powder, or standardized preparation). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

CBD, CBC, CBG, Full-spectrum hemp extract, Terpenes

Safety & Interactions

No safety data exists for cannabichromevarin in humans due to lack of clinical trials. As a cannabinoid compound, CBCV may theoretically interact with medications metabolized by CYP3A4 enzymes, including certain blood thinners and seizure medications. Potential side effects are unknown but may include cannabinoid-related effects such as drowsiness or altered blood pressure. Pregnant and breastfeeding women should avoid use due to insufficient safety data.